Genetic basis to an extraordinary response to Vinorelbine chemotherapy in metastatic triple negative breast cancer
Dr Denis Yahiaoui, Dr Marc Basik, Dr François Panet, Dr Lawrence Panasci*
Department of Oncology, Jewish General Hospital, Montreal, Canada.
*Dr Lawrence Panasci, Department of Oncology, Jewish General Hospital, Montreal, Canada.
Figure 1 : Initial CT-scan showing metastases to the lung, spleen and right axillar and mediastinal LAD.
The whole exome sequencing done in collaboration with Dr Basik's laboratory from the Lady Davis Institute for Medical Research (LDI) identified gene mutations that are thought to be deleterious; we meticulously identified each gene with a deleterious mutation and examined the function of the gene through database search/PubMed plus cross referencing the gene for possible interplay with the mitotic spindle or taxane/vinca alkaloid function/resistance, including survival and multidrug resistance-associated genes.
The following genetic abnormalities were identified by Foundation One testing: (a) amplification of CULA4, IRS-2, RAD21, RET and SDHD plus (b) a point mutation in NTRK2, TP53, ERBB4, FANCA, MLL2, NOTCH3, and SPEN. In addition to the point mutations identified in Foundation One testing, whole exome sequencing revealed several deleterious gene mutations in genes involved in the mitotic process which are of interest (KIF5A, PKHD1, CDC14A, c9orf114, CCAR1/CARP-1 and RPA2) (Table 1).
Examination of the amplified genes mentioned above indicates two important potential genes; IRS-2 and Rad21 involved in mitosis or involved in the response of tubulin-altering drugs such as vinorelbine and/or paclitaxel.
Overexpression of IRS-2 gene sensitizes MDA-MB-231 triple negative breast cancer cells to microtubule-disrupting agents such as vinorelbine but not taxol. Treatment with drugs that either stabilize or disrupt microtubules reveal that an intact microtubule cytoskeleton contributes to IRS-2 mediated activation of AKT leading to apoptosis. Indeed, breast cancer cells whose expression of IRS-2 was suppressed with short hairpin RNA had higher survival when exposed to vinca-alkoid compared to cells expressing IRS-2 (8,9,10). This differential sensitivity was not seen when the these cells were exposed to Taxol. Thus, increased expression of IRS-2 may render breast cells hypersensitive to vinorelbine but not paclitaxel.
Rad21 is a component protein of cohesion involved in chromosomal segregation and errorfree DNA repair (11, 12, 13). Overexpression of Rad21 correlates with reduced sensitivity to non-vinca alkaloid chemotherapy in-vitro (survival of triple negative breast cells correlated with the level of Rad21 expression). In a population cohort of basal like breast cancer treated with chemotherapy, overexpression of Rad21 was associated with a worse overall survival (n = 30, p = 0.002) (11,). Beside IRS-2 and Rad21, the other amplified genes do not appear to have a direct involvement in mitosis or in binding to tubulin and its associated proteins.
The whole exome sequencing identified additional interesting mutated genes involved in mitosis: one of particular interest is KIF5A, a kinesin. Kinesins are involved in chromosomal and spindle movements during mitosis (14, 15, 16). Based on functional in-vitro work with triple negative breast cells and patient cohort studies of paclitaxel nonresponders, overexpression of KIF5A was associated with resistance to paclitaxel. There were no significant difference in survival in cells overexpressing the KIF5A compared to control cells upon exposure to doxorubicin or vincristine (14).
These results suggest that overexpression of KIF5A leads to a resistance to Paclitaxel but not vinca-alkaloids (14, 17).
Besides KIF5A, the other mutated genes do not appear to have a clinically relevant chemotherapy drug resistance involving taxane and vinca alkaloids.
Our genomic analysis has led to some gene alterations which could be responsible for this patient’s extraordinary response to the vinorelbine chemotherapy (IRS2, Rad21 and KIF5A). Analyzing DNA from an unusual responder to vinorelbine allows us to determine clinically relevant DNA alterations which would make us consider vinca alkaloids earlier in a patient’s treatment course.
A. Whole exome sequencing
B. FoundationOne screening
Table 1. Genetic abnormalities were identified by A. Whole exome sequencing and B. Foundation one screening testing.
- SIFT (Sorting Intolerant From Tolerant): SIFT is a program that predict the potential impact of an amino acid substitution on protein function based on sequence homology and the physical properties of amino acids. SIFT can be deleterious, tolerated or character.
- Miglietta F, Dieci M.V, Griguolo G, Guarneri V, Conte P.F. Chemotherapy for advanced HER2negative breast cancer: Can one algorithm fit all? Cancer Treatment Reviews 60, 100–108, 2017.
- Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL,Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA,Isakoff SJ, Jankowitz RC, Javid SH,Krishnamurthy J, Leitch M, Lyons J, Matro J,Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, SmithKL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2022. J Natl Compr Canc Netw.
- Krause, W. Resistance to anti-tubulin agents: From vinca alkaloids to epothilones. Cancer Drug Resist, 2:82-106, 2019.
- Lewis SA, Lee MG, Cowan NJ. Five mouse tubulin isotypes and their regulated expression during development. J Cell Biol 1985;101:852-61.
- Akhmanova A, Steinmetz MO. Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol 2015;16:711-26.
- Hammond JW, Cai D, Verhey KJ. Tubulin modifications and their cellular functions. Curr Opin Cell Biol 2008;20:71-6.
- Silvestri R. New prospects for vinblastine analogues as anticancer agents. J Med Chem 2013;56:625-7.
- Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
- Mercado-Matos J, Clark J.L, Piper A.J, Janusis J, Shaw L.M. Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma. Cells J. Biol. Chem, 292(19) 7806–7816, 2017.
- 9.Mardilovich, K., Pankratz, S. L., and Shaw, L. M. (2009) Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun. Signal. 7, 14
- Landis, J., and Shaw, L. M. (2014) Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3 to regulate aerobic glycolysis. J. Biol. Chem. 289,18603–18613
- Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski J.M, Verschoor S, Millar
- E.K, Van der Spek P, Reis-Filho J.S, Ramsay R.G, O'Toole S.A, McNeil C.M, Sutherland R.L, McKay M.J, Fox S.B. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13:R9, 2011.
- Nasmyth K, Haering CH: Cohesin: Its Roles and Mechanisms. Annu Rev Genet 2009, 43:525558.
- Peters JM, Tedeschi A, Schmitz J: The cohesin complex and its roles in chromosome biology. Genes Dev 2008, 22:3089-3114.
- Tan MH, De S, Bebek G, Orloff M.S, Wesolowski R, Downs-Kelly E, Budd G.T, Stark G.R, Eng C. Specific kinesin expression profiles associated with taxane resistance in breast cancer. Breast Cancer Res Treat, 131(3): 849–858, 2012.
- De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.Cancer Res 69(20):8035–8042. doi:10.1158/0008-5472.CAN-09-1224
- Hirokawa N, Noda Y (2008) Intracellular transport and kinesin superfamily proteins, KIFs:structure, function, and dynamics. Physiol Rev 88(3):1089–1118.doi:10.1152/physrev.00023.2007
- De S, Cipriano R, Jackson M.W, Stark G.R. Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells. Cancer Res, 69(20):8035–42, 2009.